Ronald D Boyd Net Worth

The estimated Net Worth of Ronald D Boyd is at least $399 Thousand dollars as of 15 December 2017. Ronald Boyd owns over 25,000 units of Rockwell Medical Inc stock worth over $275,930 and over the last 21 years Ronald sold RMTI stock worth over $123,200.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ronald Boyd RMTI stock SEC Form 4 insiders trading

Ronald has made over 11 trades of the Rockwell Medical Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Ronald exercised 25,000 units of RMTI stock worth $162,500 on 15 December 2017.

The largest trade Ronald's ever made was exercising 25,000 units of Rockwell Medical Inc stock on 15 December 2017 worth over $162,500. On average, Ronald trades about 4,645 units every 100 days since 2003. As of 15 December 2017 Ronald still owns at least 67,300 units of Rockwell Medical Inc stock.

You can see the complete history of Ronald Boyd stock trades at the bottom of the page.

What's Ronald Boyd's mailing address?

Ronald's mailing address filed with the SEC is 1912 WEST HAMPTON POINT DRIVE, , STATESBORO, GA, 30458.

Insiders trading at Rockwell Medical Inc

Over the last 21 years, insiders at Rockwell Medical Inc have traded over $3,082,721 worth of Rockwell Medical Inc stock and bought 689,891 units worth $3,959,861 . The most active insiders traders include Robert L Chioini, David S.Rbi Private Investm..., and Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of $170,433. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth $43,724.

What does Rockwell Medical Inc do?

rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www

Complete history of Ronald Boyd stock trades at Rockwell Medical Inc

Rockwell Medical Inc executives and stock owners

Rockwell Medical Inc executives and other stock owners filed with the SEC include:

• Raymond Pratt,
  Chief Development Officer
• Ajay Gupta,
  Chief Scientific Officer
• Dr. Russell H. Ellison M.Sc., M.D., MSc.,
  Pres, CEO & Director
• Dr. Raymond Dennis Pratt FACP, M.D.,
  Chief Devel. Officer
• Russell L. Skibsted M.B.A.,
  Exec. VP, CFO & Chief Bus. Officer
• John Cooper,
  Independent Director
• Mark Ravich,
  Independent Director
• John McLaughlin,
  Independent Chairman of the Board
• Robert Radie,
  Independent Director
• Marc Hoffman,
  Chief Medical Officer
• Michael DeYoung,
  Vice President - Operations
• Paul McGarry,
  Principal Accounting Officer, Vice President, Corporate Controller
• Jim McCarthy,
  Senior Vice President - Corporate and Business Development
• Russell Skibsted,
  Executive Vice President, Chief Financial Officer and Chief Business Officer
• Russell Ellison,
  President, Chief Executive Officer, Director
• David J. Kull,
  Sec.
• Dr. Marc L. Hoffman,
  Chief Medical Officer
• Timothy T. Chole,
  Sr. VP of Sales & Marketing
• Megan C. Timmins,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Paul E. McGarry,
  VP, Corp. Controller & Principal Accounting Officer
• Tim Chole,
  VP of Marketing
• Anne Boardman,
  VP of Sales and Strategic Accounts
• James A. McCarthy,
  Sr. VP of Bus. & Corp. Devel.
• Michael Costello,
  Gen. Counsel
• David S.Rbi Private Investm...,
  
• Patrick J Bagley,
  Director
• Ronald D Boyd,
  Director
• Robin L Smith,
  Director
• Kenneth L Holt,
  Director
• Allen Nissenson,
  Director
• Stuart M Paul,
  Chief Executive Officer
• Brothers, Inc.Richmond Davi...,
  
• Benjamin Wolin,
  Director
• Lisa N Colleran,
  Director
• Mark H Ravich,
  Director
• David Kull,
  Principal Accounting Officer
• David S.Rbi Private Investm...,
  
• Angus W. Smith,
  Chief Financial Officer
• David S.Rbi Private Investm...,
  
• Mark Strobeck,
  President and CEO
• David A Hagelstein,
  10% owner
• Annamaria T Kausz,
  VP of Drug Development
• Robert L Chioini,
  Chairman, President and CEO
• Richard C Yocum,
  VP - Clin. Dev. & Med. Affairs
• Thomas E Klema,
  Vice President, CFO
• Megan C. Timmins,
  EVP, CLO and Secretary
• David S.Rbi Private Investm...,
  
• Joan Lau,
  Director
• Jesse Neri,
  SVP, FINANCE